

Editorial

An Issue Particular To Biomedicines: Parasitic Infection And Immunity.

Marie Pereira and Gebrela Santos-Gomes.

Student Research Center, Faculty of Medicine, Tarbiat Modares University, Tehran, Iran.

INTRODUCTION

Animal and human infectious parasite illnesses continue to be a major global health concern. Protozoan-caused parasitic diseases are linked to significant health expenditures for both humans and animals as well as direct and indirect financial loss. The main human protozoan parasite illnesses, which result in 82.4 million Disability Adjusted Life Years and 810,000 fatal cases annually, are predicted to have a prevalence of about 790 million individual cases, according to [1].

The majority of protozoan parasitic diseases are linked to economically disadvantaged populations [1], unsanitary water supplies and conditions [2], and host immunodeficiency [3]. These diseases are frequently spread by vectors (vector-borne diseases), contaminated food (food-borne diseases), or water (water-borne diseases). An integrative and multidisciplinary strategy is necessary for the control and prevention of these protozoan parasites because many of them are zoonotic [4]. *Leishmania* spp., *Trypanosoma brucei*, *Toxoplasma gondii*, *Plasmodium falciparum*, *Giardia duodenalis*, *Cryptosporidium parvum* protozoan parasites, and *Rhipicephalus bursa*, a multi-host hard tick that spreads several economically significant pathogens in ruminants, such as *Babesia*, *Anaplasma*, *Theileria*, *Rickettsia*, and *Coxiella*, as well as several zoonotic pathogens, are all covered in the nine research papers in this Special Issue of Biomedicines (MDPI), "Parasitic Infection and Immunity" [5]. These studies fall into three major categories: vaccine and therapeutic development, protozoan parasitic immunology, and novel biological characteristics of protozoan parasites.

NOVEL BIOLOGICAL FEATURES OF PROTOZOAN INSECTS

Basic biology discoveries could aid in the creation of novel therapeutic medications by illuminating the molecular

strategies used by protozoan parasites to endure in their hosts. Marucci and colleagues [7] sequenced four *Giardia lamblia* viruses and examined their biological characteristics, whereas Karamysheva and associates [6] disclosed novel biological features of *Leishmania* spp. in this Special Issue. *Leishmania* species are dimorphic protozoan parasites that are spread by sand fly vector bites. They alternate between non-flagellated amastigotes that live in the phagolysosomal compartment of mammalian macrophages and flagellated, extracellular promastigotes that reside in the vector's midgut. Prophylactic tools are scarce, and available treatment medications are linked to hazardous side effects and the quick evolution of drug-resistant strains. Karamysheva and colleagues [6] investigated the C14-demethylase (CD14DM) enzyme, which catalyzes the formation of ergostane-based sterols, to uncover the function of lipids in regulating gene expression. Since *Leishmania* produces ergostane-based sterols rather of cholesterol like mammals do, CD14DM is a promising therapeutic target. According to in vitro research, L.major CD14DM inactivation results in lower virulence, hypersensitivity to stress, increased plasma membrane fluidity, and mitochondrial dysfunction. The researchers discovered that CD14DM *Leishmania* deletion mutants showed signs of gene dysregulation, which resulted in decreased translation, increased DNA degradation, and a compromised heat shock response. It was also mentioned that the identification of the process causing RNA instability brought on by sterol deficiencies would open up new therapeutic targets for the creation of anti-*Leishmania* medications.

High-throughput sequencing of four *Giardia lamblia* viruses (GLVs) from human and animal isolates was described in the study created by Marucci and associates [7]. The flagellated protozoa parasite *G. duodenalis* colonizes the small intestine and causes diarrhea in both people and animals, including cattle and pets. Children and young animals are more vulnerable to this infection, which is mostly linked to

***Corresponding Author:** Marie Pereira, Student Research Center, Faculty of Medicine, Tarbiat Modares University, Tehran, Iran.

Received: 07-Jan-2025, ; **Editor Assigned:** 08-Jan-2025 ; **Reviewed:** 20-Jan-2025, ; **Published:** 28-Jan-2025,

Citation: Marie Pereira. An Issue Particular to Biomedicines: Parasitic Infection and Immunity. *Advances in Tropical Medicine*. 2025 January; 1(1).

Copyright © 2025 Marie Pereira. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

immunosuppression and inadequate cleanliness. Acute and chronic symptomatic infections can happen, even though it is usually asymptomatic in humans and animals. Moreover, *Giardia* may result in long-term extra-intestinal and gastrointestinal problems after infection [8]. New tactics to combat *G. duodenalis* have been accelerated by the rise of resistance and the high toxicity of traditional medications [9]. Research on protozoan parasite endosymbiont viruses is still in its infancy but is rapidly growing. These viruses have been linked to the severity of the illness, and treating giardiasis with them has been contemplated. However, before their use in the treatment of parasitic illnesses can be considered, basic and applied research is required [11]. The study's sequencing and integrated mass spectrometry-based proteomic analysis yielded fresh insights into the biology and organization of the GLV genome, underscoring the significance of these novel "omic" approaches in exposing the possible diversity of GLV and advancing our knowledge of protozoan endosymbionts.

IMMUNOLOGY OF PROTOZOAN PARASITIC

A constant adaptation between the parasite and its host may be the cause of the chronic course of many protozoan parasitic illnesses. Through intricate host-parasite molecular interactions, parasites and hosts have put pressure on one another throughout millions of years of co-evolution. The host initiates a number of immunological processes to eradicate the parasites as soon as they enter the body. Parasites use a variety of tactics to avoid or undermine the host's innate and adaptive immune responses in order to survive in this harsh environment. These tactics include diversifying their genome, altering the expression of the host immune system's targets, and obstructing or suppressing the host immune response [10–12]. Therefore, finding a host immune response that is successful in controlling parasitic infections and minimizing the chronicity or recurrence of disease is a key area of research in parasitic immunology. This Special Issue contains two papers that address the immunological aspects of illnesses caused by protozoa.

In order to assess the immunological response of canine hepatocytes exposed to *L. infantum* and the effect of inflammation on the metabolic activity of these cells in a milieu that mimics in vivo tissues, Rodrigues and colleagues [13] established a novel three-dimensional (3D) hepatic spheroid. The scientists came to the conclusion that 3D hepatic spheroids detect and respond to *L. infantum* parasites, resulting in an innate immune response at the price of a reduction in the liver's ability to metabolize xenobiotics. Vacas and associates investigated the possible immunomodulatory impact of *L. major*'s phosphotransferase serine/threonine protein kinase (LmjF.22.0810) both in vitro and in vivo [14]. According to the in vitro investigations,

promastigote parasites showed reduced expression levels of virulence factors in comparison to control parasites, while transgenic parasites overexpressing LmjF.22.0810 shown decreased infectivity in vitro. Furthermore, transgenic parasite-infected BALB/c mice had noticeably less footpad edema, most likely as a result of a Th2 immune response deficiency that favors Th1 cytokines. LmjF.22.0810 is a good target for researching the immune response brought on by *Leishmania* parasites, the investigators stated. *T. brucei*, the causative agent of African trypanosomiasis, which was regarded as a neglected tropical disease until recently, was the subject of research by Dias-Guerreiro and associates [15]. This parasite, which causes nagana in cattle and sleeping sickness in humans, is spread by the hematophagous dipteran *Glossina* spp. (tsetse fly) while the bug is feeding on blood. The extracellular vesicles (EVs) released by *T. b. brucei* were described by the scientists, who also looked at the immunological response that the EVs produced in a mouse macrophage cell line and lymphocytes. It was discovered that EVs promoted the development of regulatory CD4+ and CD8+ T cells while inducing the differentiation of both M1- and M2-macrophages and eliciting the increase of MHCII+, MHCII+, and MHCII+MHCII+ macrophage populations.

It's interesting to note that it was confirmed that EVs and *T. b. brucei* parasites appear to have complementary but opposing impacts on the host immune response, most likely creating a balance between parasite proliferation and immune response regulation.

Vaccine and Drug Development

The majority of protozoan parasite infections are underdiagnosed, especially those that impact tropical nations and are linked to poverty. Concerns about their control and eradication are growing as a result of the lack of anti-protozoan immunizations and the shortage of therapeutic medications linked to rising drug resistance. As a result, a significant amount of biomedical research has been devoted to finding novel compounds and targets for parasite management. The selection of antigenic peptide candidates for use in the creation of anti-tick vaccines based on sialotranscriptome data and in silico analysis is described in one paper in this Special Issue. Three other research papers also feature new compounds that were tested against protozoan parasites, such as *C. parvum*, *T. gondii*, and *P. falciparum*.

The creation of antitick vaccines, especially transmission-blocking vaccines, is an alternate method of preventing tick-borne illnesses. These vaccines alter the biology and behavior of the vector, preventing it from spreading disease. In order to find antigenic sites that might be utilized in the creation of anti-tick vaccines, Couto and colleagues [16] investigated the *R. bursa* sialosecretome using a reverse vaccinology

technique. Potential candidates for upcoming vaccination trials include two secreted (EVASIN and RICIN) and one membrane-related (MARVEL) proteins that are specific to *R. bursa* and absent from the mammalian host. These antigens were shown to be able to elicit a long-lasting and protective immune response against this tick.

Human non-bloody diarrhea is caused by *C. parvum*, especially in immunocompromised people and children living in environments with little resources. As a water-borne zoonosis, cryptosporidiosis is primarily contracted by ingestion through the fecal-oral route. The parasite cannot be completely eradicated from the host by any successful chemotherapy. S-Methylcysteine (SMC), one of the primary organosulfur components of garlic, was evaluated for its impact on *C. parvum* in vivo by Elmahallawy and colleagues [17]. In comparison to infected, non-treated mice, Swiss Albino mice showed significantly lower oocyst counts, fewer enteritis, hepatitis, and splenic lesions, lower serum hepatic transaminases and cytokine levels, and significantly higher levels of antioxidant enzymes, glutathione and superoxide dismutase, in the intestines two weeks after receiving SMC treatment. The authors came to the conclusion that SMC might be a promising and useful substance for treating infestations of *C. parvum*.

The obligatory intracellular apicomplexan parasite *T. gondii* is found throughout the world and infects almost all homeothermic animals, including humans as intermediate hosts and cats as definitive hosts. Pregnant women's placentas can vertically transfer *Toxoplasma gondii* to the fetus; in immunocompromised people, *Toxoplasma* infections can result in stillbirth and spontaneous abortion. High toxicity, adverse effects, and drug resistance are some of the issues linked to traditional pharmacological therapy. Therefore, there is an urgent need to find novel alternative therapeutic choices. In this regard, the novel spider peptide XYP1, which was discovered from the cDNA library of the spider *Lycosa coelestis*' venom gland, was examined by Liu and associates [18]. According to the authors, XYP1 exhibits strong anti-*Toxoplasma* properties both in vivo and in vitro. In particular, the spider peptide improved the survival of mice with acute *T. gondii* infection and markedly reduced the viability, invasion, and multiplication of tachyzoites in vitro. XYP1 may be a viable novel medication candidate for the treatment of toxoplasmosis because of its mechanism of action, which is linked to membrane perforation, swelling, and tachyzoite disintegration.

Plasmodium protozoan parasites are the cause of malaria, an infectious disease spread by mosquitoes. Humans and *Anopheles* mosquito females are the two hosts in the life cycle of *P. falciparum*. The clinical manifestation of the disease is caused by the sexual blood stage of Plasmodium parasites. The sexual stages of the parasite that mosquitoes

can contract are called mature gametocytes. The majority of anti-malarial medications only work against the blood stage of asexual parasites. Furthermore, controlling malaria is extremely challenging due to the development of parasite drug resistance to the existing medications, which can also raise the rates of morbidity and fatality. The design and in vitro effects of eleven organoarsenic compounds on *P. falciparum*'s asexual blood stage and sexual transmission stage were reported by Basova and colleagues [19]. In addition to inhibiting gametocyte growth and exflagellation, the authors discovered that the As-8 molecule demonstrated strong efficacy against *P. falciparum* strains that were both CQ-sensitive and CQ-resistant, with acceptable IC50 values. Additionally, there was no cytotoxic or hemolytic impact, suggesting that the As-8 molecule is harmless and primarily targets the parasite. The authors came to the conclusion that As-8 is a promising starting point for the development of new organoarsenic medications with multi-stage anti-*P. falciparum* efficacy.

CONCLUSION

In order to promote the flow of new discoveries and the high caliber of published studies, this Special Issue covers the key areas of research in protozoan parasitic diseases, including the study of parasitic immunology, basic research into the biology of protozoan parasites, and research applied to the development of new prophylactic and therapeutic tools. Innovative 3D cultures that more closely resemble tissue architecture, new research tools like genomics and proteomics, and in silico research offer the answers needed to control these diseases, many of which have been neglected for many years.

REFERENCES

1. Barrow, P.; Dujardin, J.C. Viruses of protozoan parasites and viral therapy: Is the time now right? *Virol. J.* 2020, 17, 142. [CrossRef][PubMed]
2. Omarova, A.; Tussupova, K. Protozoan Parasites in Drinking Water: A System Approach for Improved Water, Sanitation and Hygiene in Developing Countries. *Int. J. Environ. Res. Public Health* 2018, 15, 495. [CrossRef]
3. Andreani, G.; Lodge, R. Mechanisms of interaction between protozoan parasites and HIV. *Curr. Opin. HIV AIDS* 2012, 7, 276–282. [CrossRef] [PubMed]
4. Chomel, B.B. Control and prevention of emerging parasitic zoonoses. *Int. J. Parasitol.* 2008, 38, 1211–1217. [CrossRef]

5. Madreseh-Ghahfarokhi, S.; Dehghani-Samani, A. Zingiber officinalis and Eucalyptus globulus, Potent Lethal/Repellent Agents against Rhipicephalus bursa, Probable Carrier for Zoonosis. J. Arthropod Borne Dis. 2019, 13, 214–223. [CrossRef] [PubMed]
6. Karamysheva, Z.N.; Moitra, S. Unexpected Role of Sterol Synthesis in RNA Stability and Translation in Leishmania. Biomedicines 2021, 9, 696. [CrossRef] [PubMed]
7. Marucci, G.; Zullino, I. Re-Discovery of Giardavirus: Genomic and Functional Analysis of Viruses from Giardia duodenalis Isolates. Biomedicines 2021, 9, 654. [CrossRef] [PubMed]
8. Halliez, M.C.; Buret, A.G. Extra-intestinal and long term consequences of Giardia duodenalis infections. World J. Gastroenterol. 2013, 19, 8974–8985. [CrossRef] [PubMed]
9. Vivancos, V.; González-Alvarez, I. Giardiasis: Characteristics, Pathogenesis and New Insights About Treatment. Curr. Top. Med. Chem. 2018, 18, 1287–1303. [CrossRef]
10. Schmid-Hempel, P. Immune defence, parasite evasion strategies and their relevance for ‘macroscopic phenomena’ such as virulence. Philos. Trans. R. Soc. B Biol. Sci. 2009, 364, 85–98. [CrossRef]
11. Su, X.Z.; Zhang, C. Host-Malaria Parasite Interactions and Impacts on Mutual Evolution. Front. Cell. Infect. Microbiol. 2020, 10, 587933. [CrossRef] [PubMed]
12. Ebert, D.; Fields, P.D. Host-parasite co-evolution and its genomic signature. Nat. Rev. Genet. 2020, 21, 754–768. [CrossRef] [PubMed]
13. Rodrigues, A.V.; Alexandre-Pires, G. 3D-Hepatocyte Culture Applied to Parasitology: Immune Activation of Canine Hepatic Spheroids Exposed to Leishmania infantum. Biomedicines 2020, 8, 628. [CrossRef]
14. Vacas, A.; Fernández-Rubio, C. LmjF.22.0810 from Leishmania major Modulates the Th2-Type Immune Response and Is Involved in Leishmaniasis Outcome. Biomedicines 2020, 8, 452. [CrossRef]
15. Dias-Guerreiro, T.; Palma-Marques, J. African Trypanosomiasis: Extracellular Vesicles Shed by Trypanosoma brucei brucei Manipulate Host Mononuclear Cells. Biomedicines 2021, 9, 1056. [CrossRef] [PubMed]
16. Couto, J.; Seixas, G. Probing the Rhipicephalus bursa Sialomes in Potential Anti-Tick Vaccine Candidates: A Reverse Vaccinology Approach. Biomedicines 2021, 9, 363. [CrossRef] [PubMed]
17. Elmahallawy, E.K.; Elshopakey, G.E. S-Methylcysteine (SMC) Ameliorates Intestinal, Hepatic, and Splenic Damage Induced by Cryptosporidium parvum Infection Via Targeting Inflammatory Modulators and Oxidative Stress in Swiss Albino Mice. Biomedicines 2020, 8, 423. [CrossRef]
18. Liu, Y.; Tang, Y. Anti-Toxoplasma gondii Effects of a Novel Spider Peptide XYP1 In Vitro and In Vivo. Biomedicines 2021, 9, 934, Erratum in Biomedicines 2022, 10, 1176. [CrossRef] [PubMed]
19. Basova, S.; Wilke, N. Organoarsenic Compounds with In Vitro Activity against the Malaria Parasite Plasmodium falciparum. Biomedicines 2020, 8, 260. [CrossRef]